Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells.

Biochemical and biophysical research communications (2012-04-14)
Takuya Yamashita, Kazuya Nagano, So-ichiro Kanasaki, Yuka Maeda, Takeshi Furuya, Masaki Inoue, Hiromi Nabeshi, Tomoaki Yoshikawa, Yasuo Yoshioka, Norio Itoh, Yasuhiro Abe, Haruhiko Kamada, Yasuo Tsutsumi, Shin-ichi Tsunoda
ABSTRAKT

Mesothelioma is a highly malignant tumor with a poor prognosis and limited treatment options. Although cisplatin (CDDP) is an effective anticancer drug, its response rate is only 20%. Therefore, discovery of biomarkers is desirable to distinguish the CDDP-susceptible versus resistant cases. To this end, differential proteome analysis was performed to distinguish between mesothelioma cells of different CDDP susceptibilities, and this revealed that expression of annexin A4 (ANXA4) protein was higher in CDDP-resistant cells than in CDDP-susceptible cells. Furthermore, ANXA4 expression levels were higher in human clinical malignant mesothelioma tissues than in benign mesothelioma and normal mesothelial tissues. Finally, increased susceptibility was observed following gene knockdown of ANXA4 in mesothelioma cells, whereas the opposite effect was observed following transfection of an ANXA4 plasmid. These results suggest that ANXA4 has a regulatory function related to the cisplatin susceptibility of mesothelioma cells and that it could be a biomarker for CDDP susceptibility in pathological diagnoses.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Anti-ANXA4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.